ArticleNature communications2025
Vinyl cyclopropanes as a unifying platform for enantioselective remote difunctionalization of alkenes.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Asymmetric remote difunctionalization of alkenes is a longstanding challenge in synthetic chemistry, offering the potential to install two functional groups simultaneously across distal carbon atoms in a stereocontrolled manner. While ingenious strategies have been devised to achieve this transformation, a general catalytic system for remote, enantioselective hetero-carbofunctionalization and dicarbofunctionalization of alkenes has remained elusive. Here, we present a nickel/photoredox dual-catalyzed asymmetric remote 1,5-carbosulfonylation and 1,5-dicarbofunctionalization of vinyl cyclopropanes. This cascade reaction integrates radical addition, C-C bond cleavage, and cross-coupling to functionalize two distal carbon atoms with high enantioselectivity. Our protocol demonstrates broad substrate scope, excellent functional group tolerance, and significant synthetic utility, as evidenced by late-stage functionalization and product derivatization. Our mechanistic investigations support the involvement of a Ni(0)/Ni(I)/Ni(III) catalytic cycle in our system. This work establishes a versatile platform for remote alkene difunctionalization, expanding the toolbox of enantioselective synthetic methods and unlocking new avenues for complex molecule construction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.